|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases显示文摘The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC). Systemic gemcitabine chemotherapy seems effective in many cancers. We report the results of combination therapy with systemic gemcitabine, intra-arterial low-dose cisplatin and 5-FU (GEMFP). Seven patients with non-resectable advanced HCC were treated with GEMFP. One course of chemotherapy consisted of daily intra-arterial cisplatin (20 mg/body weight/hour on d 1, 10 mg/body weight per 0.5 h on d 2-5 and 8-12), followed by 5-FU (250 mg/body weight per 5 h on d 1-5 and 8-12) via an injection port. Gemcitabine at 1000 mg/m2 was administered intravenously at 0.5 h on d 1 and 8. The objective response was 57%. The response to GEMFP was as follows: complete response (no patients), partial response (four patients), stable disease (three patients), and progressive disease (no patients). The median survival period was 8 mo (range, 5-55). With regard to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 adverse reactions, seven (100%), seven, six (86%) and one (14%) patients developed leukopenia, neutropenia, thrombocytopenia and anemia, respectively. GEMFP may potentially be effective for non- resectable advanced HCC, but it has severe hematologic toxicity. | Kiminori Uka Hiroshi Aikata Shintaro Takaki Tomokazu Kawaoka Hiromi Saneto Daiki Miki Shoichi Takahashi Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2008 | World Journal of Gastroenterology2008，14，16： | 4 |
| 2 | Effects of a 24-week course of interferon-αtherapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma显示文摘AIM:To assess whether a 24-wk course of interferon (IFN)could prevent hepatocellular carcinoma(HCC) recurrence and worsening of liver function in patients with hepatitis C virus(HCV)-infected patients after receiving curative treatment for primary HCC. METHODS:Outcomes in 42 patients with HCV infection treated with IFN-α,after curative treatment for primary HCC(IFN group),were compared with 42 matched curatively treated historical controls not given IFN(non- IFN group). RESULTS:Although the rate of initial recurrence did not differ significantly between IFN group and non-IFN group (0%,44%,61%,and 67% vs 4.8%,53%,81%,and 87% at 1,3,5,and 7 years,P=0.153,respectively), IFN group showed a lower rate than the non-IFN group for second recurrence(0%,10.4%,28%,and 35% vs 0%,30%,59%,and 66% at 1,3,5 and 7 years, P=0.022,respectively).Among the IFN group,patients with sustained virologic response(SVR)were less likely to have a second HCC recurrence than IFN patients without an SVR,or non-IFN patients.Multivariate analysis identified the lack of SVR as the only independent risk factor for a second recurrence,while SVR and Child-Pugh class A independently favored overall survival. CONCLUSION:Most intrahepatic recurrences of HCV- related HCC occurred during persistent viral infection. Eradication of HCV is essential for the prevention of HCC recurrence and improvement of survival. | Soo Cheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，40： | 3 |
| 3 | Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma显示文摘AIM: To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS: We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN- alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS: The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not signifi cant, the score was signifi cantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 ± 1.42 vs 5.81 ± 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrentHCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION: Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation. | Soocheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，39： | 2 |
| 4 | Accretion of titanium carbide by electrical discharge machining with powder suspended in working显示文摘 | Furutania K Saneto A | 2001 | Fluid2001，25，4： | 1 |
| 5 | Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous POLG mutations显示文摘 | Weiss MD Saneto RP | 2010 | Muscle Nerve2010，41，6： | 1 |
| 6 | A boy with muscle weakness,hypercarbia,and the mitochondrial DNA A3243G mutation显示文摘 | Saneto RP Bouldin A | | 0，，： | 1 |
| 7 | A Mesoporous-silica-immobilized Oxovanadium Cocatalyst for the Lipase-catalyzed Dynamic Kinetic Resolution of Racemic Alcohols显示文摘 | Egi M Sugiyama K Saneto M | 2013 | Angew Chem Int Ed2013，52，： | 1 |
| 8 | Neuroimaging of mito-ehondrial disease 显示文摘 | Saneto RP Friedman SD Shaw DW | 2008 | Mitoehondrion2008，8，56： | 1 |
| 9 | Accretion of titanium carbide by electrical discharge machining with powder suspended in working fluid 显示文摘 | Furutani K Saneto A Takezawa H | 2001 | Journal of International Societies for Precision Engineering and Nanotechnology2001，25，： | 1 |
| 10 | Neuroimaging of mitochon-drial disease 显示文摘 | Saneto RP Friedman SD Shaw DW | 2008 | Mitochondrion2008，8，56： | 1 |
| 11 | Mesoporoussilica-immobilized Oxovanadium cocatalyst for the Lipase-catalyzed dynamic kinetic resolution of racemic alcohols显示文摘 | EGI M SUGIYAMA K SANETO M | 2013 | Angewandte Chemie InternationalEdition2013，52，： | 1 |
| 12 | Accretion of titanium carbide by electrical discharge machining with powder suspended in working fluid 显示文摘 | Katsushi Furutani Akinori Saneto Hideki Takezawa | 2001 | Precision Engineering2001，25，： | 1 |
| 13 | Beneficial effects of living-donor liver transplantation on esophageal varices显示文摘 | Tomokazu Kawaoka Shoichi Takahashi Hiroshi Aikata Takahiro Azakami Hiromi Saneto Shintaro Takaki Soo Cheol Jeong Toshimasa Asahara Katsuhide Ito Kazuaki Chayama | 2008 | Journal of Gastroenterology2008，，12： | 1 |
| 14 | Current oral and non-oral routes of antiepileptic drug delivery显示文摘 | Anderson GD Saneto RP | 2012 | Adv Drug Delivery Rev2012，64，10： | 1 |
| 15 | Vagus nerve stimulation for Intractable seizures in children 显示文摘 | Saneto RP Sotero de Menezes MA Ojemann JG | 2006 | Pediatr Neurol2006，35，5： | 1 |
| 16 | Neuroimaging of mitochon- drial disease显示文摘 | Saneto RP Friedman SD Shaw DW | 2008 | Mitochondrion2008，8，： | 1 |
| 17 | Neuroimaging of mitochondrial disease 显示文摘 | Saneto RP Friedman SD Shaw DW | 2008 | Mitochondrion2008，8，： | 1 |
| 18 | Neuroimaging of mitochondrial disease 显示文摘 | Saneto RP Friedman SD Shaw DW | 2008 | Mitochondrion2008，8，56： | 1 |
| 19 | Accretion of titanium carbide by electrical discharge machining with powder suspended in working显示文摘 | Furutania K Saneto A | 2001 | Fluid2001，25，4： | 1 |
| 20 | Accretion of titanium carbide by electrical discharge machining with powder suspended in working fluid显示文摘 | Furutania K Saneto A Takezawa H | 2001 | Precision Engineering2001，25，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员